Rapid Test For Monkeypox? NY-Based Chembio Diagnostics Thinks They Can Pull It Off


Chembio Diagnostics Inc CEMI is evaluating the potential to develop a monkeypox rapid point-of-care (POC) test. 

  • Chembio is exploring the technical requirements for test development leveraging its multiple technology platforms, DPP, SURE CHECK, and STAT PAK, along with funding partners and the broader market opportunity.
  • "We are in dialogue with leading health organizations at the federal and state level to evaluate the need for a rapid test to detect and diagnose monkeypox. We are assessing the market needs, timing, regulatory pathway, and investment required to develop a test," said Richard Eberly, President & CEO. 
  • There are now over 11,000 total confirmed monkeypox cases in the United States.
  • Currently, the FDA has cleared one test to detect monkeypox, offered through the U.S. Centers for Disease Control and Prevention (CDC) as a lab-developed test (LDT). The test utilizes a swab sample from a monkeypox lesion, creating the need for earlier detection to limit the spread.
  • Chembio's proprietary DPP technology platform provides high-quality, rapid diagnostic results in 15 - 20 minutes using a small drop of blood from the fingertip or alternative samples. 
  • The DPP platform can detect up to eight test results from a single patient sample through advanced multiplexing.
  • Price Action: CEMI shares are down 1.18% at $0.86 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksHealth CareGeneralBriefsMonkeypox
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!